Table 1.

In vitro inhibitory activity against human and mouse ATX for the most promising compounds identified, using recombinant ATX at a final concentration of 2 nM and lysophosphatidylcholine (LPC) 16:0 as a substrate. The mode of inhibition is also mentioned.

Compound	Pubchem CID	Name	Structure	IC50 (μΜ) [hATX/mATX]	Inhibition of 2nd/3rd Reaction	IC50 (μΜ) PDE Assay	Mode of Inhibition
KM03601	2820206	ethyl 3-benzylsulfanyl-4-hydroxy-6-(4-methylphenyl)-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylate		30.5/14.9	no	n.d.	competitive
KM-14	1201991	ethyl 1-benzyl-6-bromo-5-hydroxy-2-(piperidin-1-ylmethyl)-1H-indole-3-carboxylate		13.8/5.9	no	n.d.	mixed
KM-24	46379015	ethyl 1-[2-[2-(4-chlorophenyl)sulfanyl-1H-indol-3-yl]acetyl]piperidine-4-carboxylate		14.6/6.5	no	n.d.	mixed
KM-26	4662990	1-(3,4-dimethoxyphenyl)-N-(3-methoxyphenyl)-3,4-dihydro-1H-pyrrolo[1,2-a]pyrazine-2-carbothioamide		5.6/7.4	yes	2.8	competitive
KM-28	46925664	N-(2,6-dimethylphenyl)-2-[4-oxo-3-(2-thiophen-2-ylethyl)quinazolin-2-yl]sulfanylacetamide		1.8/3.0	no	0.9	n.d.
SCR01013	5702991	(3Z)-3-[[1-(Benzenesulfonyl)indol-2-yl]methylidene]-1H-indol-2-one		79.0/67.0	no	n.d.	n.d.
SC-41	20867222	4-{[4-(2-Methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]sulfonyl}-2,1,3-benzothiadiazole		13.6/4.0	no	n.d.	uncompetitive
SC-49	3540718	N-[2-(4-nitrophenyl)-4,6-dihydrothieno[3,4-c]pyrazol-3-yl]naphthalene-1-carboxamide		10.2/9.7	no	73.0	n.d.
HA155	46856189	[4-[[4-[(Z)-[3-[(4-fluorophenyl)methyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]phenoxy]methyl]phenyl]boronic acid		0.0025 (reported: 0.0057 [67])/n.d.	n.d.	n.d.	competitive
PF-8380	25265312	3,5-Dichlorobenzyl 4-(3-oxo-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)propyl)piperazine-1-carboxylate		0.0025 (reported: 0.0017 [51])/n.d.	no	0.0011	competitive
GLPG1690	90420193	2-[[2-ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]-methylamino]-4-(4-fluorophenyl)-1,3-thiazole-5-carbonitrile		0.229 (reported: 0.131 [23])/n.d.	n.d.	n.d.	n.d.